Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people (TA455)
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for treating plaque psoriasis in children and young people